Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of amenamevir patient-initiated therapy for recurrent herpes labialis
jRCT2080224870Phase 3Completed
- Sponsor
- Maruho Co., Ltd.
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in herpes labialis comparing Amenamevir 1200 mg with Placebo (2 arms). Primary endpoint: Time to complete lesion healing. Started Sep 2019; status: completed.
02
Drugs
Amenamevir
03
Conditions
herpes labialis
Beyond the preview
Go deeper on jRCT2080224870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224870.